Your browser doesn't support javascript.
loading
A Survey of Adverse Event Reporting Practices Among US Healthcare Professionals.
Stergiopoulos, Stella; Brown, Carrie A; Felix, Thomas; Grampp, Gustavo; Getz, Kenneth A.
Afiliação
  • Stergiopoulos S; Tufts Center for the Study of Drug Development, Tufts Medical School, 75 Kneeland Street, Ste 1100, Boston, MA, 02111, USA. stella.stergiopoulos@tufts.edu.
  • Brown CA; Tufts Center for the Study of Drug Development, Tufts Medical School, 75 Kneeland Street, Ste 1100, Boston, MA, 02111, USA.
  • Felix T; Amgen Inc., Washington, DC, USA.
  • Grampp G; Amgen Inc., Thousand Oaks, CA, USA.
  • Getz KA; Tufts Center for the Study of Drug Development, Tufts Medical School, 75 Kneeland Street, Ste 1100, Boston, MA, 02111, USA.
Drug Saf ; 39(11): 1117-1127, 2016 11.
Article em En | MEDLINE | ID: mdl-27638657
ABSTRACT

INTRODUCTION:

The under-reporting of adverse drug events (ADEs) is an international health concern. A number of studies have assessed the root causes but, to our knowledge, little information exists relating under-reporting to practices and systems used for the recording and tracking of drug-related adverse event observations in ambulatory settings, institutional settings, and retail pharmacies.

OBJECTIVES:

Our objective was to explore the process for reporting ADEs in US hospitals, ambulatory settings, and retail pharmacies; to explore gaps and inconsistencies in the reporting process; and to identify the causes of under-reporting ADEs in these settings.

METHODS:

The Tufts Center for the Study of Drug Development (Tufts CSDD) interviewed 11 thought leaders and conducted a survey between May and August 2014 among US-based healthcare providers (HCPs) in diverse settings to assess their experiences with, and processes for, reporting ADEs.

RESULTS:

A total of 123 individuals completed the survey (42 % were pharmacists; 27 % were nurses; 15 % were physicians; and 16 % were classified as 'other'). HCPs indicated that the main reasons for under-reporting were difficulty in determining the cause of the ADE, given that most patients receive multiple therapies simultaneously (66 % of respondents); that HCPs lack sufficient time to report ADEs (63 % of respondents); poor integration of ADE-reporting systems (53 % of respondents); and uncertainty about reporting procedures (52 % of respondents).

DISCUSSION:

The results of this pilot study identify that key factors contributing to the under-reporting of ADEs relate to a lack of standardized process, a lack of training and education, and a lack of integrated health information technologies.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Atitude do Pessoal de Saúde / Sistemas de Notificação de Reações Adversas a Medicamentos Tipo de estudo: Prognostic_studies Limite: Humans País como assunto: America do norte Idioma: En Ano de publicação: 2016 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Atitude do Pessoal de Saúde / Sistemas de Notificação de Reações Adversas a Medicamentos Tipo de estudo: Prognostic_studies Limite: Humans País como assunto: America do norte Idioma: En Ano de publicação: 2016 Tipo de documento: Article